0.40
1.96%
-0.008
After Hours:
.3836
-0.0164
-4.10%
BiomX Inc stock is currently priced at $0.40, with a 24-hour trading volume of 147.89K.
It has seen a -1.96% decreased in the last 24 hours and a +5.35% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.4126 pivot point. If it approaches the $0.3954 support level, significant changes may occur.
Previous Close:
$0.408
Open:
$0.429
24h Volume:
147.89K
Market Cap:
$22.09M
Revenue:
-
Net Income/Loss:
$-26.56M
P/E Ratio:
-0.5333
EPS:
-0.75
Net Cash Flow:
$-22.29M
1W Performance:
-16.49%
1M Performance:
+5.35%
6M Performance:
+26.86%
1Y Performance:
+36.10%
BiomX Inc Stock (PHGE) Company Profile
Name
BiomX Inc
Sector
Industry
Phone
972 7 23942377
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
BiomX Inc Stock (PHGE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Apr-15-21 | Initiated | Ladenburg Thalmann | Buy |
BiomX Inc Stock (PHGE) Latest News
BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)
GlobeNewswire Inc.
BiomX Announces the Appointment of Susan Blum to its Board of Directors
GlobeNewswire Inc.
Here's Why BiomX (PHGE) Is a Great 'Buy the Bottom' Stock Now
Zacks Investment Research
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
GlobeNewswire Inc.
BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024
GlobeNewswire Inc.
BiomX Inc Stock (PHGE) Financials Data
BiomX Inc (PHGE) Net Income 2024
PHGE net income (TTM) was -$26.56 million for the quarter ending September 30, 2023, a +19.23% increase year-over-year.
BiomX Inc (PHGE) Cash Flow 2024
PHGE recorded a free cash flow (TTM) of -$22.29 million for the quarter ending September 30, 2023, a +28.56% increase year-over-year.
BiomX Inc (PHGE) Earnings per Share 2024
PHGE earnings per share (TTM) was -$0.65 for the quarter ending September 30, 2023, a +41.44% growth year-over-year.
About BiomX Inc
BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
Cap:
|
Volume (24h):